ISRAEL is in the process of developing a new anti-COVID-19 pill and has big chances of being used because of its potential, effectiveness, and for successfully creating antibodies in pigs last March.
Oramed Pharmaceuticals, the one responsible for creating the vaccine, believes the pill could be a game-changer since the world is suffering from limited and insufficient supplies of vaccines, and is now talking about possible booster shots. The pill could easily reach countries with inadequate vaccine supplie.
According to Oramed, the single dose pill called Oravax will be suitable as it doesn’t need to be stored in low temperature storage facilities just like the current vaccines and can be administered even without the help of health professionals.
The first trial for Oravax will involve 24 people, all unvaccinated, and will be taking one or two pills. The team will monitor the pill’s effectivity, safety, and capability to produce immunity before it goes to bigger phase 3 trials.
Nadav Kidron, the CEO of Oramed Pharmaceuticals, said Oravax will train the immune system against three proteins instead of the single protein from other vaccines.
While the world is struggling to get sufficient supplies, Kidron believes that the Oravax vaccine in pill form would help countries with low inoculation rates because of its survival rate in delivery.